Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

BMC Cancer

Giusy Gentilcore⁵  Gabriele Madonna⁵  Nicola Mozzillo⁵  Antoni Ribas²  Antonio Cossu¹  Giuseppe Palmieri³  Paolo A Ascierto⁴ 

[1] Department of Pathology, Hospital-University Health Unit (AOU), Sassari, Italy

[2] Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA

[3] Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Sassari, Italy

[4] Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, 80131, Naples, Italy

[5] Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy

关键词: Melanoma therapy;    Growth inhibition;    Dabrafenib;    BRAF inhibitor;   

Others  :  1079973
DOI  :  10.1186/1471-2407-13-17

 received in 2012-03-25, accepted in 2012-11-13,  发布年份 2013

【 摘 要 】

Background

Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations.

Methods

Three melanoma cell lines were tested: M257 wild-type BRAF, LCP BRAFV600R and WM266 BRAFV600D. The MTT assays were performed using standardized approaches. To evaluate the inhibition of MAPK pathway and the consequent inhibition of cellular proliferation, the phosphorylation of ERK was examined by Western Blot analysis performed on total protein extracts from cell lines after treatment with dabrafenib.

Results

Our experiments demonstrated an effective action of Dabrafenib (GSK2118436) and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations.

Conclusion

These results could be helpful to enlarge the number of melanoma patients who may benefit of a more effective targeted treatment.

【 授权许可】

   
2013 Gentilcore et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Nissan MH, Solit DB: The “SWOT” of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Curr Oncol Rep 2011, 13:479-487.
• [2]Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
• [3]Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV: Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin Cancer Res 2012, 18:3242-3249.
• [4]Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini MC, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G: BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012, 30:2522-2529.
• [5]Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F: RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70:5518-5527.
• [6]Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
• [7]Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2012, 25:248-258.
• [8]Trefzer UD, Minor D, Ribas A, Lebbe C, Siegfried A, Arya N, Guckert M, Schadendorf D, Kefford R, Grob JJ, Hamid O, Amaravadi R, Simeone E, TWilhelm T, Kim K, Goodman V, Ascierto PA: BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2 118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Res 2011, 24:1020. abstract LBA1-1
• [9]Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.